Maze Therapeutics Inc (MAZE)

Apr 08, 2025

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Apr 08, 2025

Apr 04, 2025

Guggenheim Reiterates Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - Defense World

Apr 04, 2025

Apr 04, 2025

Leerink Partnrs Has Bearish Forecast for MAZE Q1 Earnings - Defense World

Apr 04, 2025

Mar 31, 2025

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewswire

Mar 31, 2025

Mar 31, 2025

Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year - TipRanks

Mar 31, 2025

Mar 31, 2025

Maze Therapeutics Turns Profitable: $52M Net Income as Clinical Trials Progress - Stock Titan

Mar 31, 2025

Mar 26, 2025

Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (NASDAQ:MAZE) - Seeking Alpha

Mar 26, 2025

Mar 20, 2025

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Mar 20, 2025

Mar 20, 2025

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 20, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025

Mar 05, 2025

Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period To End on March 12th - Defense World

Mar 05, 2025

Mar 01, 2025

Leerink Partners Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat

Mar 01, 2025

Mar 01, 2025

Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.6%Still a Buy? - MarketBeat

Mar 01, 2025

Feb 28, 2025

Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat

Feb 28, 2025

Feb 28, 2025

Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat

Feb 28, 2025

Feb 28, 2025

Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Feb 28, 2025

Feb 28, 2025

FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs - Defense World

Feb 28, 2025

Feb 28, 2025

Maze Therapeutics (NASDAQ:MAZE) Upgraded at TD Cowen - Defense World

Feb 28, 2025

Feb 27, 2025

FY2024 Earnings Estimate for MAZE Issued By Leerink Partnrs - MarketBeat

Feb 27, 2025

Feb 27, 2025

Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co. - Defense World

Feb 27, 2025

Feb 27, 2025

Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Guggenheim - Defense World

Feb 27, 2025

Feb 27, 2025

Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Leerink Partnrs - Defense World

Feb 27, 2025

Feb 26, 2025

Maze Therapeutics initiated with a Buy at TD Cowen - TipRanks

Feb 26, 2025

Feb 26, 2025

Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners - Defense World

Feb 26, 2025

Feb 25, 2025

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829 - TipRanks

Feb 25, 2025

Feb 25, 2025

Cowen initiates Maze Therapeutics stock with Buy rating By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 25, 2025

Maze Therapeutics receives positive ratings following recent IPO - Investing.com

Feb 25, 2025

Feb 25, 2025

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 25, 2025

Feb 25, 2025

Guggenheim sets $19 target on Maze Therapeutics stock By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 25, 2025

Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target -February 25, 2025 at 06:43 am EST - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target -February 25, 2025 at 06:32 am EST - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics - TipRanks

Feb 25, 2025

Feb 25, 2025

Maze Therapeutics initiated with an Outperform at Leerink - TipRanks

Feb 25, 2025

Feb 25, 2025

Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market - TipRanks

Feb 25, 2025

Feb 25, 2025

JPMorgan sets Maze Therapeutics stock to Overweight with $30 target By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 22, 2025

This New Drug Mimics The Health Effects of Living at High Altitude - ScienceAlert

Feb 22, 2025

Feb 18, 2025

Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month LowShould You Sell? - MarketBeat

Feb 18, 2025

Feb 16, 2025

Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month Low – Here’s Why - Armenian Reporter

Feb 16, 2025

Feb 15, 2025

Maze Therapeutics (NASDAQ:MAZE) Shares Down 3.9%Here's Why - MarketBeat

Feb 15, 2025

Feb 13, 2025

Maze Therapeutics begins Phase 2 trial for kidney disease drug - MSN

Feb 13, 2025

Feb 10, 2025

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Feb 10, 2025

Feb 10, 2025

Maze Therapeutics doses first subject in Phase II AKD treatment trial - Yahoo Finance

Feb 10, 2025

Feb 09, 2025

Maze Therapeutics’ $140 Million Upsized Initial Public Offering - Global Legal Chronicle

Feb 09, 2025

Feb 07, 2025

Cyclo Therapeutics reports promising NPC1 treatment findings - MSN

Feb 07, 2025

Feb 07, 2025

Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Investing.com Australia

Feb 07, 2025

Feb 07, 2025

Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire

Feb 07, 2025

Feb 07, 2025

Groundbreaking Kidney Disease Trial: Maze's APOL1 Inhibitor Targets 1M+ Patient Market - StockTitan

Feb 07, 2025

Feb 06, 2025

Maze Therapeutics stock hugs flat line following $140M IPO - MSN

Feb 06, 2025

Feb 03, 2025

Sionna eyes up $156M IPO to fund cystic fibrosis trials - Fierce Biotech

Feb 03, 2025

Feb 01, 2025

Metsera, Maze land on NASDAQ as IPO queue grows - BioCentury

Feb 01, 2025

Jan 31, 2025

Biotech firm Maze Therapeutics raises $140 million in US IPO - MSN

Jan 31, 2025

Jan 31, 2025

Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut - MSN

Jan 31, 2025